Merck & Co ends deal with SurModics
This article was originally published in Scrip
Merck & Cohas discontinued its licence and research collaboration with the US-based drug delivery companySurModics, following a strategic review of its business and product development portfolio. SurModics said that the decision was not based on any concerns over the safety or efficacy of its I-vation TA, the I-vation platform or any of its other sustained drug delivery systems. SurModics is currently in licensing discussions with other companies and said that it would continue to work with its partners to meet their required timelines in developing products for the treatment of eye diseases.